Home Archive
Archive
2024 Volume 55 Issue 2  Published: 2024-02-10
    Review
  • Pingping LAN , Hui WANG , Hua LIU , Tiantian WANG , Zengtao WANG
    doi: 10.16522/j.cnki.cjph.2024.02.001

    As the first mitogen-activated protein kinase kinase kinase 5(MAP3K5) inhibitor in the clinical stage, indications of selonsertib in clinical trials included non-alcoholic steatohepatitis, pulmonary arterial hypertension and diabetic kidney disease. Due to its novel and unique structure, it has become the main lead compound for structural design and backbone modification of this class of inhibitors. In recent years, a large number of “me-too” candidates had been obtained from selonsertib by the structure modification. This paper introduces the progress of structure modification strategies and structure-activity relationships of selonsertib from two aspects of skeleton fragment modification and cyclization structure modification, aiming to provide a reference for research in this field.

  • Review
  • Wenpeng ZHAO
    doi: 10.16522/j.cnki.cjph.2024.02.002

    Antibody-drug conjugates (ADC) combine the targeting ability of monoclonal antibodies and the potent cytotoxicity of small molecule substances, becoming a research focus in the current biopharmaceutical field. Although various ADCs have been marketed globally, challenges still exist in formulation and stability. This review outlines the key points and difficulties in ADC formulation development and clinical application from the perspectives of antibody, linker, and small molecule substance selection for ADC, and proposes a stability study plan during ADC use, aiming to provide references for the future ADC development.

  • Review
  • Ruixi LI , Chuang WANG , Yan LIU , Yuzhou CHEN , Beibei XIANG
    doi: 10.16522/j.cnki.cjph.2024.02.003

    This review introduces the principles, structures and development directions of commonly used ultrafine pulverizing equipment. The application of ultrafine pulverization technology in preparation of traditional Chinese medicines is systematically outlined, including enhancing the wall breaking rate, refining the physicochemical properties, promoting the extraction, elevating the efficacy of medicinal components, and streamlining subsequent processing of traditional Chinese medicines. Then, the combining principles of particle design technology with traditional Chinese medicine powder technology are elucidated. Additionally, methods for determining particle size and evaluating cell wall breaking rates, as well as the conduction of pharmacokinetic-pharmacodynamic studies of traditional Chinese medicine ultrafine powder are proposed. Ultimately, the development prospects of ultrafine pulverization technology are discussed, and the issues that urgently need resolution are summarized, with the aim of providing references for the application of ultrafine pulverization technology in preparation of traditional Chinese medicines.

  • Review
  • Hang CHEN , Changzhao JIANG , Pu CHEN , Wenxin NIU , Jincui YE
    doi: 10.16522/j.cnki.cjph.2024.02.004

    Microneedle is a painless transdermal drug delivery system that has become a hot topic in drug formulation development in recent years due to its numerous advantages of avoiding the first-pass effect, maintaining smooth blood concentration, and providing high bioavailability, good safety and patient compliance. However, despite these benefits, there are several challenges associated with microneedle technology, including poor biocompatibility, limited drug loading capacity, unstable drug release, and restricted mechanical properties. The microneedle materials play a crucial role in determining the direction of clinical applications, drug-loading capability, and drug stability. This review summarizes and organizes the research progress made in the field of various new microneedle materials, as well as highlights their potential applications and prospects, hoping to provide a valuable reference for the development of microneedle formulations.

  • Review
  • Jing XIA , Yulan YANG , Xiaodong CHEN , Xiaofei WANG
    doi: 10.16522/j.cnki.cjph.2024.02.005

    In recent years, with the frequent occurrence of respiratory diseases such as chronic obstructive pulmonary disease and asthma, pulmonary administration has gradually become a new trend in the treatment of these diseases. And inhalation administration is one of the more widely used ways. In the development of inhalation, there is often a certain amount of amorphous material present in the active pharmaceutical ingredients, excipients, and intermediates due to the processes such as micronization and grinding. Amorphous material has poor thermal stability and can easily transform into the crystalline under certain conditions, which can potentially cause many issues, such as affecting the stability of the final products. Therefore, whether it is a single compound or an intermediate obtained according to a prescription, a mature drug development process must include the detection and quantitative analysis of amorphous material in the drug. This review mainly elaborates on the detection methods commonly used in the pharmaceutical field for the amorphous content.

  • Review
  • Baoqing FAN , Zhenyu WANG
    doi: 10.16522/j.cnki.cjph.2024.02.006

    Technology transfer is crucial throughout the entire lifecycle of biological macromolecules. Given the intricate structure and the unpredictable production of biological macromolecules, this review categorizes the technology transfer of production process of biological macromolecules into two phases: preclinical and early clinical sample production, as well as pivotal clinical and commercialization stage sample production. Depending on the objectives and tasks of each phase, key control points for technology transfer in production processes, encompassing cell lines, raw materials, production processes, safety evaluation of exogenous factors, and comparability studies, are identified. And the corresponding technology transfer strategies are suggested, accompanied by a compilation of common challenges faced during the technology transfer process of biological macromolecules, with the aim to serve as a guide for biopharmaceutical companies in their technology transfer for production process.

  • Paper
  • Hao ZHOU , Xiaoyu SHI , Mengyao LIU , Kuikui LIU , Wenjie REN
    doi: 10.16522/j.cnki.cjph.2024.02.007

    4-Bromo-3-(1,3-dioxolane-2-yl)phenol(3) was synthesized by condensation of 2-bromo-5-hydroxybenzaldehyde(2) with ethylene glycol in toluene under the catalysis of p-toluenesulfonic acid and pyridine. The addition of pyridine buffered the acidity of p-toluenesulfonic acid and solved the problems of reversible reaction and polymer formation. 4-[4-Bromo-3-(1,3-dioxolane-2-yl)phenoxy]benzonitrile(4) was synthesized from 3 and 4-fluorobenzonitrile under the action of anhydrous potassium carbonate and tetrabutylammonium bromide. The phase transfer catalyst made the reaction faster. 4-(4-Bromo-3-formylphenoxy)benzonitrile(5) was obtained by deprotection of 4. Miyaura borylation of 5 with bis(pinacolato)diboron catalyzed by [1,1'-bis(diphenylphosphino) ferrocene]-dichloropalladium[Pd(dppf)Cl2] produced 4-[3-formyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]-benzonitrile(6), which avoided the flammable and explosive reagents and intermediates and strict operation conditions. After reduction with sodium borohydride, crisaborole(1) was obtained by cyclization. Sodium borohydride was added dropwise in the form of aqueous solution(containing 5% NaOH) to make the operation safer and more convenient. The total yield of the improved synthesis was 51.7%(based on 2), with the purity more than 99.9%.

  • Paper
  • Chao DONG , Hanyue YANG , Xianguang YAN , shubo DONG , Dahua SHI
    doi: 10.16522/j.cnki.cjph.2024.02.008

    In this article, based on the industrial synthetic route of alogliptin benzoate(1), seven related substances of 1 were synthesized, namely 2,2'-[[6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidine-1,5(2H)-diyl]-bis(methylene)]-dibenzonitrile(7), 2-[[5-bromo-6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidine-1(2H)-yl]-methyl]benzonitrile(8), 2,2'-[[6-ethoxy-3-methyl-2,4-dioxo-3,4-dihydropyrimidine-1,5(2H)-diyl]bis(methylene)]-dibenzonitrile(9), (R)-2-[[3-methyl-2,4-dioxo-6-[(piperidin-3-yl)amino]-3,4-dihydropyrimidine-1(2H)-yl]methyl]-benzonitrile(10), (R)-2-[[6-[3-[[3-(2-cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl]amino]-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidine-1(2H)-yl]methyl]benzonitrile(11), (R)-2-[[3-methyl-6-[3-[(1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl)amino]piperidin-1-yl]-2,4-dioxo-3,4-dihydropyrimidine-1(2H)-yl]methyl]benzonitrile(12), (R)-N-[1-[3-(2-cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl]piperidin-3-yl]benzamide(13). Their structures were confirmed by 1H NMR, 13C NMR and MS. The synthesis of 7, 9, 12, and 13 were reported at the first time.

  • Paper
  • Zhen LI , Sujie CHEN , Guoquan ZHAO
    doi: 10.16522/j.cnki.cjph.2024.02.009

    Eight related substances of ceritinib(1) were prepared according to its structure and synthetic process, namely 5-chloro-2-isopropoxy-N-[2-(isopropylsulfonyl)phenyl]pyrimidin-4-amine(related substance A), 5-chloro-4-[[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-ol(related substance B), 5-chloro-N2-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N4-[2-(isopropylsulfinyl)phenyl]pyrimidine-2,4-diamine(related substance C), 5-chloro-N2-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N4-[2-(propylsulfonyl)phenyl]pyrimidine-2,4-diamine(related substance D), 5-chloro-N4-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N2-[2-(isopropylsulfonyl)phenyl]-pyrimidine-2,4-diamine(related substance E), 2-[[5-chloro-4-[[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-yl]amino]-4-methyl-5-(piperidin-4-yl)phenol(related substance F), 4-[4-[4-[[5-chloro-4-[[2-(isopropylsulfonyl)-phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidin-1-yl]pentan-2-one(related substance G),5-chloro-N2-[4-[1-[5-chloro-4-[[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-yl]piperidin-4-yl]-2-isopropoxy-5-methylphenyl]-N4-[2-(isopropylsulfonyl)phenyl]pyrimidine-2,4-diamine(related substance H). And their structures were confirmed by 1H NMR and MS.

  • Paper
  • Xiaoping FANG , Haoxue ZHENG , Shan LU , Yan CAO
    doi: 10.16522/j.cnki.cjph.2024.02.010

    Amorphization is an effective method to improve the solubility and dissolution of poorly water-soluble drugs. However, the poor stability limits the further development of amorphous drugs. Therefore, this study aimed to explore the stability mechanism of the andrographolide-oxymatrine(AP-OMT) co-amorphous system from the perspective of molecular aggregation. At first, the AP-OMT co-amorphous system were prepared by solvent volatilization method. Then, molecular dynamics simulations were used to calculate and evaluate the compatibility within the components. Finally, Gaussian 16 software was used to calculate the bond energies and bond distances of molecular aggregates consisting of multiple hydrogen bonding modes in the co-amorphous AP-OMT, which were verified by stability investigation. Quantum computing studies revealed that dimer 4 had the largest interaction energy(with negative value) and the shortest hydrogen bond length, indicating that dimer 4 was the most stable aggregate in the co-amorphous system. Stability studies showed that the AP-OMT co-amorphous system was physically stable over a period of 12 months. This study revealed the stability mechanism of the binary co-amorphous system of AP-OMT and provided theoretical guidance for the stability study of this class of drugs.

  • Paper
  • Jin CAO , Renjie XU , Jianhua HE , Xuecheng XIAO , Shan LU
    doi: 10.16522/j.cnki.cjph.2024.02.011

    Erlotinib hydrochloride(1) is a novel tyrosine kinase inhibitor characterized by high permeability but low water solubility. The addition of small molecule ligands to prepare co-amorphous drug systems is an effective strategy to enhance the solubility, dissolution rate, and bioavailability of poorly water-soluble drugs. In this study, co-amorphous systems of 1 and L-tryptophan(2) were prepared by rotary evaporation method. The co-amorphous 1-2 system was characterized by Fourier transform infrared spectroscopy(FTIR), powder X-ray diffraction(PXRD), and differential scanning calorimetry(DSC). The PXRD and DSC results confirmed the formation of the co-amorphous system. And FTIR analysis and molecular dynamics simulations further suggested the presence of hydrogen bond interactions between 1 and 2, which could be the potential molecular mechanism for the formation of the co-amorphous system. Compared to the single crystal of 1, the solubility and dissolution rate of 1 in the 1-2 co-amorphous system were significantly improved. The results of pharmacokinetic modeling in SD rats showed that the cmax and AUC0→t of the co-amorphous system group were 2.8 times and 2.3 times higher than those of the bulk drug group, respectively. Meanwhile, there was no significant increase in the cmax and AUC0→t of the physical mixture group. In conclusion, the co-amorphous 1-2 system prepared in this study can significantly improve the solubility and oral bioavailability of 1.

  • Paper
  • Junwei JIA , Zhixiang ZHU , Zhengzhao LI , Yujiang PANG , Liping ZHANG , Zhong FENG
    doi: 10.16522/j.cnki.cjph.2024.02.012

    In this study, elagolix sodium self-developed tablets were formulated by optimizing three key formulation process parameters, namely the particle size of active pharmaceutical ingredient(API), the aperture of sieve screen in the dry granulation process, and the tablet hardness. The similarity factor (f2) values between the dissolution curves of the self-developed and reference tablets were calculated as a criterion for evaluation. The results indicated that when the API particle size[d(0.9)] was 250 μm, the aperture of sieve screen was 1.4 mm, and the tablet hardness was 80 N, the in vitro dissolution behavior of the self-developed tablets was similar to that of the reference formulations. Subsequently, bioequivalence was investigated using relevant permeation parameters from the parallel artificial membrane permeation assay(PAMPA) and pharmacokinetic characteristics in Beagle dogs. The results revealed that the permeation rates of the self-developed tablets and the reference formulations were 8.698 8 and 8.161 6 μg·mL–1·min–1 respectively, with membrane permeabilities of 2.24×10–4 and 2.10×10–4 cm/s. The confidence interval for the self-developed tablets ranged from 100.82% to 104.54%. There was no statistically significant difference in the pharmacokinetic parameters between the two groups(P>0.05). The relative bioavailability of the self-developed tablets was found to be (95.4±8.69)%, demonstrating the bioequivalence with the reference formulations.

  • Paper
  • Zhijun WANG , Ruiqi YUE , Qilei CHENG , Yanhai ZHANG , Huiyi LI
    doi: 10.16522/j.cnki.cjph.2024.02.013

    An ultra high performance liquid chromatography(UHPLC) method was established to determine the fifteen related substances in bromhexine hydrochloride(1). The Zorbax Eclipse Plus C18 column was used, with ammonium formate buffer-acetonitrile(60∶40) as the mobile phase. The final chromatographic conditions were screened out by examining the conditions such as mobile phase pH, buffer salt concentration, and column temperature. The UHPLC method and pharmacopoeia standard method were used to analyze and compare a total of sixteen batches of 1 bulk drugs and 1 tablets from three manufacturers, and high-resolution mass spectrometry was used to preliminarily infer the unknown impurities. The results showed that the fifteen related substances and principal component were well separated, and the products after forced degradation did not interfere with the separation of the target peak, indicating the good specificity of this method. All known impurities and total impurities in 1 bulk drugs and 1 tablets met the requirements of the pharmacopoeia. The unknown impurity was analyzed by LC-MS, and it was inferred that it might be 2,4-dibromo-6-[[methyl-(4-methylcyclohexyl)-amino]methyl]aniline. This method provided a reference for the consistency evaluation of 1.

  • Paper
  • Panpan WU , Chunhe WANG , Xiaoju JIANG , Yunfei YUE , Changyu WANG
    doi: 10.16522/j.cnki.cjph.2024.02.014

    An HPLC-ELSD method was established to determine the contents of phosphatidyl ethanolamine(2)and egg yolk phosphatidylcholine(3) in lecithin(1) tablets. The CAPCELL PAK C18 column(4.6 mm×250 mm,5 μm) was used, and the analysis was carried out in the gradient elution mode with methanol-water-glacial acetic acid-triethylamine(85∶15∶0.45∶0.05) as mobile phase A, and n-hexane-isopropanol-mobile phase A(20∶48∶32) as mobile phase B. The results showed that it was linear for 2 and 3 in the ranges of 2 - 50 and 20 - 400 μg/mL, respectively. The average recoveries(n=6) of 2 and 3 were 102.9% and 106.6%, respectively, with RSDs of 2.6% and 1.4%. The content determination results showed that in six batches of 1 tablets, the contents of 2 and 3 were 1.5 - 5.0 and 40.0 - 65.0 mg per tablet, respectively. The established method has good specificity and accuracy, which can be used for the determination of 2 and 3 in 1 tablets.

  • Paper
  • Xiaoyan SHI , Yujiang PANG , Zhixiang ZHU , Zengyu PAN , Liping ZHANG , Zhong FENG
    doi: 10.16522/j.cnki.cjph.2024.02.015

    An HPLC method was established for the determination of the related substances in carbidopa and levodopa sustained-release tablets. The Waters X-Bridge C18 column(4.6 mm×250 mm, 5 μm) was used, and the analysis was carried out in the gradient elution mode with pH 1.8 phosphate buffer solution as mobile phase A, and pH 1.8 phosphate buffer solution-methanol(250∶750) as mobile phase B. The flow rate was 1.0 mL/min, the detection wavelength was 280 nm, the column temperature was 25 ℃, and the injection volume was 20 μL. The results showed that the main peaks and related substance peaks could be well separated, and it was linear for carbidopa, levodopa, and the seven related substances. The average recoveries(n=9) of seven related substances were 98.97%, 100.79%, 102.69%,98.13%, 102.34%, 95.97%, and 100.80%, respectively. The results of the forced degradation tests showed that this method could indicate the degradation products under various conditions. This method has higher specificity, simplicity, and durability than the methods included in the USP 43. It can be used for the production control and stability sample determination of carbidopa and levodopa sustained release tablet.

  • Paper
  • Hua ZHENG , Honghua LU , Yanqin HE , Guizhou HAO , Guimin ZHANG
    doi: 10.16522/j.cnki.cjph.2024.02.016

    A gas chromatography-mass spectrometry(GC-MS) method was established to determine the genotoxic impurities of benzyl chloride(2) and benzyl dichloride(3) in fulvestrant injection(1). The VF-1ms capillary column(0.25 mm×30 m×0.25 μm) was used, and two monitoring modes were respectively adopted to measure 2(MRM) and 3(SIM). The results showed that it was linear for 2 and 3 in the ranges of 5.427 - 54.272 ng/mL, 4.775 -47.748 ng/mL, respectively. The LOQs of 2 and 3 were 2.714 and 2.387 ng/mL, and the LODs were 0.54 and 0.48 ng/mL, respectively. The average recoveries(n=9) of 2 and 3 were 99.43% and 99.09%, with the RSDs of 2.43% and 2.66%, respectively. The established GC-MS method can provide references for impurity research in 1.

  • Pharmaceutical Management & Information
  • Rong JIANG , Yujie ZHENG , Fei XU , Lele ZHANG , Rong SHAO
    doi: 10.16522/j.cnki.cjph.2024.02.017
  • Pharmaceutical Management & Information
  • Wenjun ZENG , Qiufen MA , Lu HUANG
    doi: 10.16522/j.cnki.cjph.2024.02.018
  • Pharmaceutical Management & Information
  • Yifan YANG , Jinping XIE , Rong SHAO
    doi: 10.16522/j.cnki.cjph.2024.02.019
  • Pharmaceutical Management & Information
  • Yang LIU , Haihong JIANG , Rong XING
    doi: 10.16522/j.cnki.cjph.2024.02.020
News